AstraZeneca Ups Investment in Messenger RNA Drugs With Ethris Deal AstraZeneca Ups Investment in Messenger RNA Drugs With Ethris Deal

AstraZeneca has stepped up its investment in messenger RNA drugs, a promising approach in genetic therapy, by spending more than 25 million euros ($29 million) on a research alliance with German biotech start-up Ethris.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news